HIGHLIGHTS
- who: Junliang Fu and Fu-Sheng Wang from the Fourth Military Medical University, China have published the research: Immunogenicity of inactivated coronavirus disease 2019 vaccines in patients with chronic hepatitis B undergoing antiviral therapy, in the Journal: (JOURNAL) of August/27,/2021
- what: The authors compared the adverse reaction (ADR) rates and antibody levels against SARSCoV-2 in patients with CHB undergoing NAs monotherapy or Peg-IFNu03b1-based treatment, and healthy controls (HCs). The authors demonstrated that SARS-CoV2 vaccines have acceptable safety in patients with CHB undergoing different antiviral therapies.
- how: The . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.